GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2009

Regulus Raises $20M in Series A Round

  • Regulus Therapeutics secured $20 million in a series A round of financing. Alnylam Pharmaceuticals and Isis Pharmaceuticals, which together formed Regulus in September 2007, were the sole and equal investors in the financing.

    “This equity financing when combined with last year’s significant up-front payment made by GlaxoSmithKline (GSK) as part of our partnership gives Regulus cash that we expect will last at least through 2011,” says Kleanthis G. Xanthopoulos, Ph.D., president and CEO of Regulus. The firm received $20 million up front in the GSK deal, which is worth $598 million.

    “In addition, the reorganization of our capital structure to a C-Corporation sets the basis for a strong, independent company allowing us to more flexibly attract capital and continue forging relationships with the pharmaceutical industry.

    Regulus’ asset estate includes 900 patents (approximately 600 issued and 300 pending) pertaining to miRNAs as well as chemistry and technological know-how to discover and develop oligonucleotide therapeutics targeting miRNAs.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Growing Fears Over Rise in Zika Virus Infections

With the recent announcement from the World Health Organization that the Zika virus is “now spreading explosively,” are you concerned with Zika infection in your area?

More »